Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddys plans to...

    Dr Reddys plans to launch value-added drugs in US as part of diversification, market entry strategy

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-08T13:32:11+05:30  |  Updated On 17 Aug 2021 10:48 AM IST

    As part of the diversification and new market entry strategy, DRL (Dr Reddys) plans to re-focus some of its Research and Development resources to service the high potential branded generics markets such as China, Russia and other emerging markets.


    New Delhi: Maintaining that pricing pressure will continue in the US market, Dr Reddy's Laboratories has said the company plans to launch several value-added products this fiscal to offset the persisting problem.


    As part of the diversification and new market entry strategy, DRL plans to re-focus some of its Research and Development resources to service the high potential branded generics markets such as China, Russia and other emerging markets.


    "We believe that pricing pressures will continue to affect all players in generics in the US. Overcoming this necessitates a robust pipeline of complex formulations with limited competition a pipeline that allows your company to introduce several value-added products each year, and thus make up for price erosions on the earlier launched products," K Satish Reddy and GV Prasad, chairman and co-chairman respectively said in the latest annual report.


    Read Also: Dr Reddy's Laboratories in process to seek permission for launch of 70 products in China


    As many as 110 generic filings awaiting approval from the USFDA and the company has to leverage this and ensure that they succeed in delivering these products, molecule by molecule, to the US on the due dates, they said.


    "Given the challenges in the US market, we will continue our efforts to diversify our market presence," they said.


    The drugmaker said it will continue to focus on complex formulations primarily injectables and oral solid dosage forms as well as OTC brands in the medium term, and controlled substances under class II, and non-substitutable generics in the longer term, the report indicated with respect to North America generics.


    Despite concerns about a trade war between the US and China, it is not a surprise that China is still viewed as a huge market opportunity for the pharmaceutical industry, the report said.


    "We have also grown well in China and expect it to be a relatively high growth market in the next few years," it said.


    The strategy for growth in emerging markets is to continue improving the company's market share in chosen therapy areas, including the expansion of biosimilars and the oncology portfolio.


    "We will focus on scaling up in our major markets, which include Russia, China, Brazil, South Africa and Ukraine," it said.


    The report further said the pharma major will attempt to further strengthen its presence in six chosen spaces-United States, India, Russia, China, Global Hospitals including Biosimilars, and the Global API (Active Pharmaceutical Ingredients) business- to drive next level of growth.


    "Our target is to attain self-sustainability for each of our business. Despite multiple headwinds being faced by the overall industry, we are cautiously optimistic of improving our performance in FY2020 by calibrating our levers which would suit the business environment better and, thus, guide us to better performance for the year ahead," DRL said.

    active pharmaceutical ingredientsAPIbiosimilarDr Reddy'sDr Reddy's LaboratoriesDr Reddys market strategyDRLdrugsGV PrasadK Satish Reddyoncologypharmapharma newspharma news indiaprice erosionUnited StatesUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok